Chemotherapy: What Progress in the Last 5 Years?

Docetaxel. By 1999, docetaxel had become the reference agent in metastatic breast cancer, and it remains so in 2004. A randomized trial of 326 patients demonstrated superiority of docetaxel (100 mg/m 2 every 3 weeks) over doxorubicin (75 mg/m 2 every 3 weeks) as single agents in terms of response rate (48% v 33%; P Z .008). Although no survival benefit was evident